Digital Therapeutics (DTx)

Alcimed supported a European pharmaceutical laboratory in its DTx thinking, the objective of which was to formalize a roadmap for future investments in the field.

Through monitoring and internal discussions, we built an organizational and governance proposal for the laboratory by addressing key questions: how does the DTx strategy fit in with the laboratory’s portfolio? What functions should a “DTx hub” include? Which therapeutic areas are most directly affected by the topic? This roadmap was ultimately presented to the laboratory’s general management.

As part of its support for a European pharmaceutical laboratory, Alcimed regularly carries out expert appraisals and in-depth analyses of innovative start-ups and SMEs with a view to partnerships or co-development.

Several of these “targets” have a DTx positioning, and, in these analyses, Alcimed interacts directly with the companies of interest to understand their degree of maturity, their DTx value proposition, their inclinations to work with the pharmaceutical company, and their practical needs.

The desired goal, when a partnership is created, is to catalyze the emergence of the DTx industry by accelerating the marketing of digital therapies!

We supported a pharmaceutical company to take a position on a proposed buyout for a new digital pain management solution.

We characterized the key markets in pain management by segmenting them by geography and use cases, and we assessed the potential for the solution, taking into account regulatory specificities, market access specificities, cultural habits, etc.

Finally, we validated the start-up’s value proposition and recommended to our client to proceed with the technical due diligence.

We supported a European pharmaceutical company to carry out a state-of-the-art research in the field of DTX to induce behavioral change.

The objective was to define the clinical evaluation criteria that can be used to demonstrate the effectiveness of these approaches for patients with chronic diseases, in this case diabetes. We then carried out a search for active partners in the field, and we assessed the level of evidence provided by referring to the state of the art produced as well as the proposed business models.

Finally, we organized an ad-board to challenge our analysis and finalize the selection of the most relevant partners for our client.

Alcimed worked with a major pharma leader to delineate the DTx app landscape in the US for the support of hemophilia patients.

Our team identified and analyzed the existing DTx apps for hemophilia patients from various platforms to characterize their specific offers and service gaps (e.g. value proposition, partnerships, user reviews). We fully characterized the features (e.g. symptom tracking, treatment tracking) of the most interesting apps and applied a mix of detailed literature research and social listening approaches to gather user perception about the identified hemophilia DTx apps.

Thanks to our work, our client was able to get a big picture with information on the need-to-have and nice-to-have features for their own solution and recommendations from our team on the first steps to conduct for the design of their own future app.

Alcimed supported a major pharma company on the long term to ideate, develop and launch a DTx to support patients suffering from Morbus Crohn disease in Germany.

First, we conducted several interviews with HCPs and Crohn’s disease patients in Germany to identify current hurdles and pain points in the patient pathway. We then organized four different workshops to ideate and prioritize new solutions that our client could launch to efficiently support Crohn disease patients.

In the end, three concepts were selected and further developed and one concept of a DTx entered a pilot phase. Our team also supported our client in the development of the business model and in the launch plan of its DTx solution.